Pooled log HR for BRAF mutation effect on patient survival in melanoma for cohort studies was 0.57 (0.35–0.80) and the final pooled log HR including one RCT was 0.53 (0.32–0.75) corresponding to a HR of 1.70 (1.37–2.12, 95% CI). This evidence concerns the gene BRAF and melanoma.